Management of de Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and the Role of Radiation Therapy: A Consensus by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Pract Radiat Oncol. 2025 May-Jun;15(3):e286-e294. doi: 10.1016/j.prro.2024.10.007. Epub 2024 Oct 28.

Abstract

Purpose: Prostate cancer treatments paradigms are in continuous evolution, especially in the metastatic setting. In this context, the Genito-Urinary Group of Italian Association of Radiotherapy and Clinical Oncology aimed to create a consensus on radiation therapy indication in de novo metastatic hormone-sensitive prostate cancer both on primary tumor and metastatic sites.

Methods: A panel of experts, involved in clinical management of prostate cancer, through the estimate-talk-estimate method, developed a list of items and correspondent statements on the identified topic.

Results: Seven conclusive items were identified with 12 statements about the chosen topic, radiation therapy in metastatic hormone-sensitive prostate cancer on primary tumor and metastatic sites.

Conclusions: This consensus might help clinicians in prostate cancer managing in daily clinical practice.

Publication types

  • Consensus Statement

MeSH terms

  • Humans
  • Italy
  • Male
  • Neoplasm Metastasis
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / radiotherapy
  • Radiation Oncology